Edaravone: A potential treatment for the COVID-19-induced in
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In severe cases of COVID-19, an excessive and unregulated release of certain pro-inflammatory cytokines and chemokines can occur, producing an inflammatory syndrome that elicits significant systemic inflammation, multiple organ damage and failure and death. Researchers suggest that edaravone be considered for such use either alone or in combination with one or more anti-viral drugs, such as Lopinovir/Ritonavir.

Edaravone is given IV to treat amyotrophic lateral sclerosis and acute phase cerebral infarction. Edaravone is a lipophilic compound that penetrates readily into numerous tissues and organs and has significant anti-oxidant and anti-inflammatory efficacy. The systemic administration of edaravone produces protective effects against inflammation and injury to the lungs, kidneys, intestines, pancreas, brain and liver. Edaravone also decreases the levels of 1) certain cytokines (IL-2, IL-6, IL-1 beta, TNF-alpha) and chemokines (IL-8, MCP-1, MIP-1a); 2) reactive oxygen species and nitric oxide and 3) hepatic AST and ALT, in various animal models.

Edaravone’s efficacy could be determined by identifying individuals 18 years of age or older who have laboratory – confirmed COVID-19 and are diagnosed with severe COVID-19 , for a double-blind, randomized placebo-controlled trial. All patients should receive the best supportive care. The primary efficacy point would be mortality and clinical improvement would be evaluated as previously described.

In conclusion, researchers hypothesize that edaravone, if given in a timely manner, would decrease organ damage, clinical complications and mortality in severe cases of COVID-19. If edaravone decreases mortality and produces significant clinical improvement, its efficacy should be tested in infectious diseases that produce an overexuberant inflammatory response, such as Ebola.

Source: https://www.sciencedirect.com/science/article/pii/S1043661820313633?dgcid=rss_sd_all